BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 30383414)

  • 1. Lipid mediators of liver injury in nonalcoholic fatty liver disease.
    Liangpunsakul S; Chalasani N
    Am J Physiol Gastrointest Liver Physiol; 2019 Jan; 316(1):G75-G81. PubMed ID: 30383414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.
    Pierantonelli I; Svegliati-Baroni G
    Transplantation; 2019 Jan; 103(1):e1-e13. PubMed ID: 30300287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic Steatohepatitis.
    Suzuki A; Diehl AM
    Annu Rev Med; 2017 Jan; 68():85-98. PubMed ID: 27732787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis.
    Bellanti F; Villani R; Facciorusso A; Vendemiale G; Serviddio G
    Free Radic Biol Med; 2017 Oct; 111():173-185. PubMed ID: 28109892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Wu J
    Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
    Lee C; Kim J; Jung Y
    Cells; 2019 Oct; 8(10):. PubMed ID: 31619023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease.
    Farrell GC; Haczeyni F; Chitturi S
    Adv Exp Med Biol; 2018; 1061():19-44. PubMed ID: 29956204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipidomics in pathogenesis, progression and treatment of nonalcoholic steatohepatitis (NASH): Recent advances.
    Musso G; Saba F; Cassader M; Gambino R
    Prog Lipid Res; 2023 Jul; 91():101238. PubMed ID: 37244504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
    Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
    Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
    Manne V; Handa P; Kowdley KV
    Clin Liver Dis; 2018 Feb; 22(1):23-37. PubMed ID: 29128059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation.
    Ibrahim SH; Hirsova P; Gores GJ
    Gut; 2018 May; 67(5):963-972. PubMed ID: 29367207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-Related Alterations of Nonalcoholic Steatohepatitis in Sprague-Dawley Rats Fed a High-Fat and High-Cholesterol Diet.
    Omagari K; Asakawa E; Sasao M; Narita S; Hisano M; Fukuda A; Suruga K; Ichimura M; Tsuneyama K
    J Nutr Sci Vitaminol (Tokyo); 2019; 65(4):349-356. PubMed ID: 31474685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histopathological Diagnosis of Nonalcoholic Steatohepatitis (NASH).
    Giashuddin S; Alawad M
    Methods Mol Biol; 2022; 2455():1-18. PubMed ID: 35212981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rodent Models of Nonalcoholic Fatty Liver Disease.
    Zhong F; Zhou X; Xu J; Gao L
    Digestion; 2020; 101(5):522-535. PubMed ID: 31600750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apoptosis and non-alcoholic fatty liver diseases.
    Kanda T; Matsuoka S; Yamazaki M; Shibata T; Nirei K; Takahashi H; Kaneko T; Fujisawa M; Higuchi T; Nakamura H; Matsumoto N; Yamagami H; Ogawa M; Imazu H; Kuroda K; Moriyama M
    World J Gastroenterol; 2018 Jul; 24(25):2661-2672. PubMed ID: 29991872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular pathways of nonalcoholic fatty liver disease development and progression.
    Bessone F; Razori MV; Roma MG
    Cell Mol Life Sci; 2019 Jan; 76(1):99-128. PubMed ID: 30343320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive Study of Multiple Stages Progressing to Nonalcoholic Steatohepatitis with Subsequent Fibrosis in SD Rats.
    Wang L; Wu S; Cai M; Ma J; Li S; Li M; Xu Y; Wei L; Shang J
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28820447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic Stellate Cells: Dictating Outcome in Nonalcoholic Fatty Liver Disease.
    Wiering L; Subramanian P; Hammerich L
    Cell Mol Gastroenterol Hepatol; 2023; 15(6):1277-1292. PubMed ID: 36828280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.